

T S1/7

1/7/1

DIALOG(R)File 351:Derwent WPI

(c) 2003 Thomson Derwent. All rts. reserv.

008434544

WPI Acc No: 1990-321544/199043

Compsn. for external application contg. 2-dimethylamino-ethanol - to improve skin condition, reduce hair loss, etc.

Patent Assignee: ASCHEMIE MULLER R (ASCH-N); MUELLER AZCHEMIE ROBERT (MUEL-N); MULLER R (MULL-I)

Number of Countries: 014 Number of Patents: 004

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
DE 3912477	A	19901018	DE 3912477	A	19890415	199043 B
EP 396857	A	19901114	EP 90102853	A	19900214	199046
JP 2292215	A	19901203	JP 9096166	A	19900411	199103
JP 94018775	B2	19940316	JP 9096166	A	19900411	199414

Priority Applications (No Type Date): DE 3912477 A 19890415

Cited Patents: 1.Jnl.Ref; DE 2131946; GB 1182320

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
-----------	------	-----	----	----------	--------------

EP 396857	A				
-----------	---	--	--	--	--

Designated States (Regional): AT BE CH DE ES FR GB GR IT LI LU NL SE

JP 94018775	B2	3	A61K-031/13	Based on patent JP 2292215
-------------	----	---	-------------	----------------------------

Abstract (Basic): DE 3912477 A

Compsn. for external application contains 2-dimethylaminoethanol (I) plus usual formulation materials. (I) is used as a salt or ester, esp. the hydrogencarbonate, citrate, orotate, hydrogentartrate, aceglutamate, acetamidobenzoate or hydrogensuccinate.

USE/ADVANTAGE - The compsns. improve the condition (elasticity and structure) of the skin, preventing premature ageing and development of wrinkles. They also reduce androgen-dependent hair loss and stimulate hair growth. (I) increases protein synthesis and prolongs the livetime of (post)mitotic fibroblasts. (I) is already known for internal use as a psychopharmaceutical and for treatment of geriatric disorders. (3pp Dwg.No.0/0)

Derwent Class: B05; D21; E16

International Patent Class (Main): A61K-031/13

International Patent Class (Additional): A61K-007/06; A61K-007/48

?